Brokerages Anticipate West Pharmaceutical Services, Inc. (NYSE:WST) Will Announce Quarterly Sales of $665.55 Million

Brokerages expect that West Pharmaceutical Services, Inc. (NYSE:WST) will announce sales of $665.55 million for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for West Pharmaceutical Services’ earnings. The lowest sales estimate is $660.10 million and the highest is $671.55 million. West Pharmaceutical Services posted sales of $527.20 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 26.2%. The company is expected to announce its next quarterly earnings report on Thursday, July 22nd.

According to Zacks, analysts expect that West Pharmaceutical Services will report full-year sales of $2.66 billion for the current financial year, with estimates ranging from $2.64 billion to $2.68 billion. For the next year, analysts expect that the firm will report sales of $2.89 billion, with estimates ranging from $2.84 billion to $2.92 billion. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for West Pharmaceutical Services.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, April 29th. The medical instruments supplier reported $2.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.42 by $0.63. The company had revenue of $670.70 million during the quarter, compared to the consensus estimate of $614.77 million. West Pharmaceutical Services had a net margin of 18.19% and a return on equity of 25.08%.

Separately, Zacks Investment Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $355.00 price objective for the company in a research report on Wednesday, April 21st.

In other news, insider Silji Abraham sold 2,171 shares of the business’s stock in a transaction dated Monday, May 10th. The shares were sold at an average price of $335.00, for a total transaction of $727,285.00. Following the completion of the sale, the insider now owns 6,077 shares of the company’s stock, valued at $2,035,795. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.66% of the stock is owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the company. KB Financial Partners LLC purchased a new stake in shares of West Pharmaceutical Services during the first quarter worth about $106,000. Advisor Partners LLC grew its stake in West Pharmaceutical Services by 2.2% during the 1st quarter. Advisor Partners LLC now owns 2,388 shares of the medical instruments supplier’s stock valued at $673,000 after acquiring an additional 52 shares in the last quarter. Beacon Investment Advisory Services Inc. grew its stake in West Pharmaceutical Services by 6.0% during the 1st quarter. Beacon Investment Advisory Services Inc. now owns 4,794 shares of the medical instruments supplier’s stock valued at $1,351,000 after acquiring an additional 271 shares in the last quarter. Axiom Investment Management LLC purchased a new stake in West Pharmaceutical Services during the 1st quarter valued at about $1,747,000. Finally, Baker Tilly Wealth Management LLC grew its stake in West Pharmaceutical Services by 18.8% during the 1st quarter. Baker Tilly Wealth Management LLC now owns 1,536 shares of the medical instruments supplier’s stock valued at $433,000 after acquiring an additional 243 shares in the last quarter. 92.12% of the stock is owned by institutional investors and hedge funds.

Shares of West Pharmaceutical Services stock opened at $359.54 on Friday. The stock has a 50-day moving average price of $335.41. The firm has a market capitalization of $26.54 billion, a P/E ratio of 64.43, a P/E/G ratio of 1.87 and a beta of 0.99. West Pharmaceutical Services has a fifty-two week low of $215.16 and a fifty-two week high of $361.78. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.11 and a current ratio of 2.75.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, August 4th. Stockholders of record on Wednesday, July 21st will be paid a dividend of $0.17 per share. The ex-dividend date of this dividend is Tuesday, July 20th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.19%. West Pharmaceutical Services’s dividend payout ratio is currently 14.29%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components.

Read More: What does a market perform rating mean?

Get a free copy of the Zacks research report on West Pharmaceutical Services (WST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.